The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Prometheus (Inst)
 
Sandra J. Lee
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks (I)
Consulting or Advisory Role - Roche/Genentech
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Uma N. M. Rao
No Relationships to Disclose
 
Gary I Cohen
No Relationships to Disclose
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
Laura Fulper Hutchins
Research Funding - Abbott/AbbVie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Polynoma (Inst)
 
Jeffrey Alan Sosman
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Harriet M. Kluger
Consulting or Advisory Role - Alexion Pharmaceuticals; Genentech/Roche; Prometheus; Regeneron
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Vernon K. Sondak
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck/Schering Plough; Novartis; Provectus
 
Henry B. Koon
Speakers' Bureau - Bristol-Myers Squibb
 
Donald P. Lawrence
No Relationships to Disclose
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb
 
David R. Minor
Stock and Other Ownership Interests - Bristol-Myers Squibb (I)
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Theravance
Speakers' Bureau - Bristol-Myers Squibb; Merck
 
Carrie B. Lee
Travel, Accommodations, Expenses - Novartis
 
Mark R Albertini
Research Funding - Apeiron Biologics (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Lawrence E. Flaherty
Consulting or Advisory Role - Caris Life Sciences; Merck/Schering Plough
Travel, Accommodations, Expenses - Caris Life Sciences; Merck/Schering Plough
 
Teresa M. Petrella
Honoraria - Abbvie (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Bristol-Myers Squibb; Janssen (I); Merck; Novartis Canada Pharmaceuticals Inc; Roche Canada
Consulting or Advisory Role - Abbvie (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Bristol-Myers Squibb; Janssen (I); Merck; Novartis; Roche
Research Funding - Merck; Roche Canada
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Checkmate Pharmaceuticals; GreenPeptide; Novartis; Roche; Solaran RX
Research Funding - Merck (Inst); Prometheus (Inst)